Clinical trial · Interventional
Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer
Precision-Panc Master Protocol: Personalising Treatment For Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Precision-Panc Master Protocol is a "portal" protocol for patients with known or suspected pancreatic cancer to be accrued through multiple centres in the UK, with the option of being subsequently enrolled into PRIMUS (Pancreatic canceR Individualised Multi-arm Umbrella Studies) examining different treatment regimens and/or biomarker development. Eligible patients will undergo tumour biopsy and blood collection prospectively for molecular profiling at a central laboratory and the results may be used to inform enrolment to PRIMUS studies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms Pancreatic | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Biopsy Material Required for Registration
- description
- The Precision-Panc Master Protocol aims to recruit, consent and screen patients with pancreatic cancer
- interventionNames
- Other: Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling
Primary outcomes (1)
- measure
- Proving that patients with pancreatic cancer can have their tissue molecularly assessed and be followed up in a clinical trial setting
- timeFrame
- At end of study (5 years)
- description
- The number of patients screened and registered to the master protocol will be recorded. The number of patients who we are able to molecular assess will be recorded and all patients will be followed up in the master protocol until death.
Secondary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients (age \>16 years). * Either: * Presence of a hypodense pancreatic mass highly suspicious of primary pancreatic cancer with or without distant metastasis as assessed by a Pancreatic Multi-Disciplinary Team (MDT). Or o Histologically or cytologically confirmed pancreatic ductal adenocarcinoma and its variants. * Patient is willing and able to undergo additional tumour biopsy (from the primary or a metastatic site) aimed at obtaining sufficient tissue for molecular profiling if this is required. * Patient is deemed suitable to receive chemotherapy and/or radiotherapy, and/or surgery pending stage of disease at presentation. * Patient is deemed potentially eligible for a currently open PRIMUS study * Patient has signed informed consent for screening research tumour biopsy (Consent 1). * Patient has signed informed consent for Precision-Panc Master Protocol molecular profiling (Consent 2).
References
Publications (1)
- DERIVEDSaha A, Wadsley J, Sirohi B, Goody R, Anthony A, Perumal K, Ulahanan D, Collinson F. Can Concurrent Chemoradiotherapy Add Meaningful Benefit in Addition to Induction Chemotherapy in the Management of Borderline Resectable and Locally Advanced Pancreatic Cancer?: A Systematic Review. Pancreas. 2023 Jan 1;52(1):e7-e20. doi: 10.1097/MPA.0000000000002215. PMID 37378896